|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Imperial College London |
|---|---|
| Collaborator: |
Organon |
| Information provided by: | Imperial College London |
| ClinicalTrials.gov Identifier: | NCT00239590 |
Purpose
Testosterone has traditionally been regarded as a risk factor for heart disease due to the fact that males have a higher incidence of this disease than women, at least until the menopause. However recent studies have shown that men with low levels of testosterone may be at an increased risk of developing coronary heart disease (furring up of the blood vessels supplying blood to the heart). Our group has demonstrated a relaxing effect of testosterone in isolated animal coronary arteries (blood vessels supplying blood to the heart). We have shown that short-term testosterone administration can increase coronary artery and brachial artery (blood vessel in the arm) blood flow and can decrease the lack of blood supply to the heart muscle in men with coronary artery disease. These findings indicate a need for similar but longer-term studies to investigate the possible beneficial effects of longer-term testosterone therapy on the heart and blood vessels. Should this treatment be shown to be beneficial to men with coronary artery disease it may be a useful additional therapy for men with the furring up of arteries in the heart and the resulting angina.
Aim To investigate our hypothesis that testosterone can beneficially affect myocardial perfusion, vascular reactivity, metabolic risk factors for coronary heart disease and improve quality of life in men with low plasma testosterone levels and coronary heart disease.
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Heart Disease |
Drug: Testosterone undecanoate |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Crossover Assignment, Bio-equivalence Study |
| Official Title: | Effects of Chronic Testosterone on Myocardial Ischaemia and Endothelial Function in Men With Documented Coronary Heart Disease |
| Study Start Date: | June 2001 |
| Estimated Study Completion Date: | April 2004 |
The main purpose of this project is to determine whether testosterone treatment over a number of weeks can beneficially affect myocardial perfusion, vascular reactivity, metabolic risk factors and quality of life in men with documented coronary heart disease. Men with documented significant coronary artery disease and a positive exercise test for myocardial ischaemia will be enrolled into the study. They will be randomised to active testosterone therapy (5 mg/day) or placebo for 2 months. After 2 months they will undergo MRI perfusion scanning, radial artery applanation tonometry to assess endothelial function, blood sampling for analysis of metabolic risk factors for coronary heart disease, complete quality of life questionnaires and will cross-over to the opposite treatment. After a further 2 month period these tests will be repeated. Angina diaries will be kept for the duration of the study.
Eligibility| Ages Eligible for Study: | 35 Years to 75 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United Kingdom | |
| Royal Brompton & Harefield NHS Trust | |
| London, United Kingdom, SW3 6NP | |
| Principal Investigator: | Peter Collins, MA MD FRCP | Imperial College London |
More Information
| Study ID Numbers: | 2000AE13B |
| Study First Received: | October 13, 2005 |
| Last Updated: | October 13, 2005 |
| ClinicalTrials.gov Identifier: | NCT00239590 History of Changes |
| Health Authority: | United Kingdom: Research Ethics Committee |
|
Arterial Occlusive Diseases Heart Diseases Antineoplastic Agents, Hormonal Antineoplastic Agents Myocardial Ischemia Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Vascular Diseases Arteriosclerosis Methyltestosterone |
Hormones Pharmacologic Actions Testosterone 17 beta-cypionate Coronary Disease Anabolic Agents Testosterone Therapeutic Uses Cardiovascular Diseases Coronary Artery Disease Androgens |